Please login to the form below

Not currently logged in
Email:
Password:

Janssen joins Evotec-Harvard programme to tackle cause of diabetes

J&J division could pay out $300m per product developed

Janssen Evotec Harvard Curebeta diabetes
Janssen Pharmaceuticals has entered an agreement with Evotec and Harvard University to research drugs to treat the cause of diabetes rather than its symptoms.

Janssen, a division of Johnson & Johnson (J&J), will pay up to $300m in milestones per product developed as part of the programme, in addition to an upfront payment of $8m to be shared between Evotec and Massachusetts-based Harvard.

If any drugs are commercialised, Janssen will also pay royalties on any products sold, with this again shared between Evotec and Harvard.

The deal is an expansion of an existing partnership between Evotec and Harvard, known as the CureBeta research and development programme, and focuses on both type 1 and type 2 diabetes.

Co-led by Dr Doug Melton and Dr Cord Dohrmann, CureBeta was established by Harvard, the Howard Hughes Medical Institute (HHMI), and Evotec in 2011 to bring industry and academia together to better identify and develop targets that could cause the regeneration of insulin-producing beta cells.

People with diabetes either have a lack of or malfunction of these cells, and triggering a regrowth could herald a new era in diabetes treatments that focus on the cause of the condition rather than its related effects, such as increased levels of blood sugar.

The collaboration so far has yielded several potential targets and a portfolio of small molecules and biologics, with Janssen now stepping in to provide research support as well as expertise in both pharmaceutical development and marketing.

"As the funding and licensing landscape has evolved in the pharmaceutical industry, we have evolved to identify new development strategies for our research assets,” said Isaac Kohlberg, Harvard's chief technology development officer and head of its Office of Technology Development.

“This alliance with Janssen Pharmaceuticals represents an important step towards a real solution for the treatment of diabetes."

This deal is just the latest in a line of industry collaborations to research the cause of diabetes.

In February, 2012, Boehringer Ingelhiem announced it was entering a five-year partnership with Technische Universität (TU) in Dresden, Germany, focused on the cause of type 1 diabetes, while Novo Nordisk is teaming up the JDRF (Juvenile Diabetes Research Foundation.

Not-for-profit organisation the JDRF also has ongoing research projects into type 1 diabetes with Roche and Eli Lilly & Company.

12th July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Agnitio

Agnitio is a leading supplier of state-of-the-art multichannel communication. Specialists in digital communication tools for the global life sciences industry,...

Latest intelligence

Precision medicine and the changing role of the healthcare professional
The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of...
How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma...
eyeforpharma Barcelona 2017 highlights: Industry at the brink of transformation
Hear what Anthill's delegates reported back from the biggest eyeforpharma Barcelona yet....

Infographics